EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Venous thromboembolism after joint arthroplasty: where do we stand with aspirin?

Andrea Zampoli, Goksel Dikmen, Ali Parsa, Seyed Mohammad Javad Mortazavi, Rocco Papalia, Javad Parvizi

EFORT Open Reviews · 2026-11-01 · 11 (11) · 1228-1235

DOI: 10.1530/eor-2026-0129 ↗
AbstractBibliografische Angaben

Abstract

Abstract Venous thromboembolism prophylaxis after total joint arthroplasty remains heterogeneous, particularly regarding the role of aspirin within modern fast-track pathways. Although aspirin is widely used in North American arthroplasty practice, European guidelines remain more conservative and often provide limited or non-operational recommendations for its use after total hip and knee arthroplasty. Contemporary evidence supports aspirin as a viable prophylactic option in selected patients, with potential advantages related to its safety profile, cost, ease of administration and reduced treatment burden. The clinical role of aspirin should be interpreted within a risk-stratified framework that accounts for thromboembolic risk, bleeding risk, surgical complexity, early mobilization and duration of prophylaxis. Available evidence, including recent randomized data, supports aspirin-based prophylaxis in appropriately selected patients, both as part of sequential strategies and, increasingly, as monotherapy within contemporary fast-track pathways. This scoping review synthesizes current guideline-level evidence and contemporary clinical data to clarify practical considerations for agent selection, dosing, duration and aspirin-based prophylaxis after total joint arthroplasty.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →